Cortagen vs Humanin

Brain cortex-derived tetrapeptide that modulates gene expression in neural and cardiac tissue through chromatin regulatory mechanisms; microarray analysis demonstrates broad transcriptional effects following administration.

Cortagen is a synthetic tetrapeptide (Ala-Glu-Asp-Pro) classified as a Khavinson-class bioregulator derived from cerebral cortex tissue, investigated for gene expression regulatory effects in neural and cardiac tissue. As a Khavinson-class bioregulator, cortagen is proposed to modulate transcriptional activity in aging target tissue by interacting with gene regulatory elements; microarray analysis of cardiac gene expression following cortagen administration has demonstrated broad effects on transcriptional profiles across multiple functional gene categories, suggesting tissue-regulatory activity beyond its cortical tissue origin. Published research on Khavinson-class peptides has further characterized the systematic gene expression regulatory potential of short bioregulator peptides across tissue types, providing the mechanistic context within which cortagen's transcriptional effects are interpreted. Cortagen has no FDA approval or regulatory approval in any major Western jurisdiction; evidence derives from Khavinson-series preclinical studies with no independent clinical trials published in Western-indexed journals. Cortagen benefits investigated in preclinical research include neuroprotective effects in neural tissue, cardiovascular gene expression modulation, and support for vascular wall integrity in aged animal models. As a brain cortex-derived Khavinson bioregulator, cortagen is proposed to regulate transcription in neural and cardiac tissue through chromatin-level mechanisms, potentially preserving tissue-specific gene expression patterns that decline with aging. Research interest encompasses cortagen's role in neurological aging, post-ischemic brain tissue recovery in preclinical models, and combined bioregulator protocols that pair cortagen with cardiovascular and metabolic peptides for comprehensive longevity applications. Cortagen is a research compound with no regulatory approval in any jurisdiction; evidence is limited to preclinical studies and Russian clinical research literature, with no independent randomized trials published in Western peer-reviewed journals.

Mitochondria-derived peptide; binds gp130 receptor, activates STAT3/JAK pathway; inhibits BAX-mediated apoptosis; improves insulin sensitivity

Humanin is a mitochondrially encoded 21-amino-acid peptide originally identified through its capacity to suppress neuronal apoptosis induced by familial Alzheimer's disease gene products, now recognized as a founding member of the class of mitochondrial-derived peptides (MDPs) with broad cytoprotective actions in neurons, cardiomyocytes, and other metabolically stressed cell types. Humanin exerts its cytoprotective effects through multiple mechanisms: extracellularly, it binds insulin-like growth factor-binding protein 3 (IGFBP-3) to regulate IGFBP-3's interaction with nuclear import machinery and modulate its proapoptotic signaling; intracellularly, it inhibits c-Jun NH2-terminal kinase (JNK) activation through SH3-binding protein 5 to suppress stress-induced apoptotic cascades. PNAS research established that humanin interacts with IGFBP-3 to regulate cell survival and apoptosis, characterizing a molecular basis for its anti-apoptotic activity, and subsequent work identified JNK inhibition as an additional neuroprotective mechanism in humanin-treated neuronal preparations. Humanin is a research compound with no regulatory approval in any jurisdiction; published evidence is predominantly from in vitro and preclinical models, and no human clinical trials have been completed to establish pharmacokinetic, safety, or efficacy parameters for exogenous humanin administration.